Clinical trial
Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory…
NCT00003144 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00003144 |
|---|---|
| Title | Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors |
| Official title | Phase I Study of Amifostine (Ethyol) as a Cytoprotector of Gemcitabine/Cisplatin Combination |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, cisplatin, gemcitabine hydrochloride |
| Enrollment | 44 |
| Start date | Aug 1, 1997 |
| Primary completion | Apr 1, 2001 |
| First posted | Apr 27, 2004 |
| Last update posted | Mar 28, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: